TrialLeukemia & lymphoma2021

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.

Sanjal Desai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.